Search Results - "Weirather, Jason L"

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma by Rodig, Scott J, Gusenleitner, Daniel, Jackson, Donald G, Gjini, Evisa, Giobbie-Hurder, Anita, Jin, Chelsea, Chang, Han, Lovitch, Scott B, Horak, Christine, Weber, Jeffrey S, Weirather, Jason L, Wolchok, Jedd D, Postow, Michael A, Pavlick, Anna C, Chesney, Jason, Hodi, F Stephen

“…Combination anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) and anti-programmed cell death protein 1 (PD-1) therapy promotes antitumor immunity and provides…”
Get more information

Comprehensive comparison of Pacific Biosciences and Oxford Nanopore Technologies and their applications to transcriptome analysis [version 2; peer review: 2 approved] by Weirather, Jason L, de Cesare, Mariateresa, Wang, Yunhao, Piazza, Paolo, Sebastiano, Vittorio, Wang, Xiu-Jie, Buck, David, Au, Kin Fai

“…Background: Given the demonstrated utility of Third Generation Sequencing [Pacific Biosciences (PacBio) and Oxford Nanopore Technologies (ONT)] long reads in…”
Get full text

Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade by Gu, Shengqing Stan, Zhang, Wubing, Wang, Xiaoqing, Jiang, Peng, Traugh, Nicole, Li, Ziyi, Meyer, Clifford, Stewig, Blair, Xie, Yingtian, Bu, Xia, Manos, Michael P, Font-Tello, Alba, Gjini, Evisa, Lako, Ana, Lim, Klothilda, Conway, Jake, Tewari, Alok K, Zeng, Zexian, Sahu, Avinash Das, Tokheim, Collin, Weirather, Jason L, Fu, Jingxin, Zhang, Yi, Kroger, Benjamin, Liang, Jin Hua, Cejas, Paloma, Freeman, Gordon J, Rodig, Scott, Long, Henry W, Gewurz, Benjamin E, Hodi, F Stephen, Brown, Myles, Liu, X Shirley

“…Immune checkpoint blockade (ICB) therapy revolutionized cancer treatment, but many patients with impaired MHC-I expression remain refractory. Here, we combined…”
Get more information

Characterization of fusion genes and the significantly expressed fusion isoforms in breast cancer by hybrid sequencing by Weirather, Jason L, Afshar, Pegah Tootoonchi, Clark, Tyson A, Tseng, Elizabeth, Powers, Linda S, Underwood, Jason G, Zabner, Joseph, Korlach, Jonas, Wong, Wing Hung, Au, Kin Fai

“…We developed an innovative hybrid sequencing approach, IDP-fusion, to detect fusion genes, determine fusion sites and identify and quantify fusion isoforms…”
Get full text

MAPS: pathologist-level cell type annotation from tissue images through machine learning by Shaban, Muhammad, Bai, Yunhao, Qiu, Huaying, Mao, Shulin, Yeung, Jason, Yeo, Yao Yu, Shanmugam, Vignesh, Chen, Han, Zhu, Bokai, Weirather, Jason L., Nolan, Garry P., Shipp, Margaret A., Rodig, Scott J., Jiang, Sizun, Mahmood, Faisal

“…Highly multiplexed protein imaging is emerging as a potent technique for analyzing protein distribution within cells and tissues in their native context…”
Get full text

Serial Quantitative PCR Assay for Detection, Species Discrimination, and Quantification of Leishmania spp. in Human Samples by WEIRATHER, Jason L, JERONIMO, Selma M. B, DONELSON, John E, WILSON, Mary E, GAUTAM, Shalini, SUNDAR, Shyam, KANG, Mitchell, KURTZ, Melissa A, HAQUE, Rashidul, SCHRIEFER, Albert, TALHARI, Sinesio, CARVALHO, Edgar M

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Interferon Regulatory Factor 6 Promotes Differentiation of the Periderm by Activating Expression of Grainyhead-Like 3 by de la Garza, Gabriel, Schleiffarth, Jack Robert, Dunnwald, Martine, Mankad, Anuj, Weirather, Jason L., Bonde, Gregory, Butcher, Stephen, Mansour, Tamer A., Kousa, Youssef A., Fukazawa, Cindy F., Houston, Douglas W., Manak, J Robert, Schutte, Brian C., Wagner, Daniel S., Cornell, Robert A.

“…IFN regulatory factor 6 (IRF6) is a transcription factor that, in mammals, is required for the differentiation of skin, breast epithelium, and oral epithelium…”
Get full text

Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade by Buchbinder, Elizabeth I., Weirather, Jason L., Manos, Michael, Quattrochi, Brian J., Sholl, Lynette M., Brennick, Ryan C., Bowling, Peter, Bailey, Nancy, Magarace, Lisa, Ott, Patrick A., Haq, Rizwan, Izar, Benjamin, Giobbie‐Hurder, Anita, Hodi, F. Stephen

“…Mucosal melanoma is a rare form of melanoma which arises from melanocytes in the mucosal membranes and can be effectively treated with immune checkpoint…”
Get full text

Single cell expression analysis of primate-specific retroviruses-derived HPAT lincRNAs in viable human blastocysts identifies embryonic cells co-expressing genetic markers of multiple lineages by Glinsky, Gennadi, Durruthy-Durruthy, Jens, Wossidlo, Mark, Grow, Edward J., Weirather, Jason L., Au, Kin Fai, Wysocka, Joanna, Sebastiano, Vittorio

“…Chromosome instability and aneuploidies occur very frequently in human embryos, impairing proper embryogenesis and leading to cell cycle arrest, loss of cell…”
Get full text

A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013 by Ademuyiwa, Foluso O., Gao, Feng, Street, Cherease R., Chen, Ina, Northfelt, Donald W., Wesolowski, Robert, Arora, Mili, Brufsky, Adam, Dees, E. Claire, Santa-Maria, Cesar A., Connolly, Roisin M., Force, Jeremy, Moreno-Aspitia, Alvaro, Herndon, John M., Carmody, Madelyn, Davies, Sherri R., Larson, Sarah, Pfaff, Kathleen L., Jones, Stephanie M., Weirather, Jason L., Giobbie-Hurder, Anita, Rodig, Scott J., Liu, Zheng, Hagemann, Ian S., Sharon, Elad, Gillanders, William E.

“…Atezolizumab with chemotherapy has shown improved progression-free and overall survival in patients with metastatic PD-L1 positive triple negative breast…”
Get full text

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial by Schoenfeld, Jonathan D, Giobbie-Hurder, Anita, Ranasinghe, Srinika, Kao, Katrina Z, Lako, Ana, Tsuji, Junko, Liu, Yang, Brennick, Ryan C, Gentzler, Ryan D, Lee, Carrie, Hubbard, Joleen, Arnold, Susanne M, Abbruzzese, James L, Jabbour, Salma K, Uboha, Nataliya V, Stephans, Kevin L, Johnson, Jennifer M, Park, Haeseong, Villaruz, Liza C, Sharon, Elad, Streicher, Howard, Ahmed, Mansoor M, Lyon, Hayley, Cibuskis, Carrie, Lennon, Niall, Jhaveri, Aashna, Yang, Lin, Altreuter, Jennifer, Gunasti, Lauren, Weirather, Jason L, Mak, Raymond H, Awad, Mark M, Rodig, Scott J, Chen, Helen X, Wu, Catherine J, Monjazeb, Arta M, Hodi, F Stephen

“…Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and PD-L1 (PD[L]-1)-targeted therapy have poor outcomes. Studies suggest that…”
Get full text

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative by Patel, Sanjay S., Weirather, Jason L., Lipschitz, Mikel, Lako, Ana, Chen, Pei-Hsuan, Griffin, Gabriel K., Armand, Philippe, Shipp, Margaret A., Rodig, Scott J.

“…Classic Hodgkin lymphoma (cHL) is a tumor composed of rare, atypical, germinal center–derived B cells (Hodgkin Reed-Sternberg [HRS] cells) embedded within a…”
Get full text

A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma by Cader, Fathima Zumla, Hu, Xihao, Goh, Walter L., Wienand, Kirsty, Ouyang, Jing, Mandato, Elisa, Redd, Robert, Lawton, Lee N., Chen, Pei-Hsuan, Weirather, Jason L., Schackmann, Ron C. J., Li, Bo, Ma, Wenjiang, Armand, Philippe, Rodig, Scott J., Neuberg, Donna, Liu, X. Shirley, Shipp, Margaret A.

“…PD-1 blockade is highly effective in classical Hodgkin lymphomas (cHLs), which exhibit frequent copy-number gains of CD274 ( PD-L1 ) and PDC1LG2 ( PD-L2 ) on…”
Get full text

Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial by Schoenfeld, Jonathan D, Hanna, Glenn J, Jo, Vickie Y, Rawal, Bhupendra, Chen, Yu-Hui, Catalano, Paul S, Lako, Ana, Ciantra, Zoe, Weirather, Jason L, Criscitiello, Shana, Luoma, Adrienne, Chau, Nicole, Lorch, Jochen, Kass, Jason I, Annino, Donald, Goguen, Laura, Desai, Anupam, Ross, Brendan, Shah, Hina J, Jacene, Heather A, Margalit, Danielle N, Tishler, Roy B, Wucherpfennig, Kai W, Rodig, Scott J, Uppaluri, Ravindra, Haddad, Robert I

“…Novel approaches are needed to improve outcomes in patients with squamous cell carcinoma of the oral cavity. Neoadjuvant immunotherapy given prior to surgery…”
Get more information

Combined protein and nucleic acid imaging reveals virus-dependent B cell and macrophage immunosuppression of tissue microenvironments by Jiang, Sizun, Chan, Chi Ngai, Rovira-Clavé, Xavier, Chen, Han, Bai, Yunhao, Zhu, Bokai, McCaffrey, Erin, Greenwald, Noah F., Liu, Candace, Barlow, Graham L., Weirather, Jason L., Oliveria, John Paul, Nakayama, Tsuguhisa, Lee, Ivan T., Matter, Matthias S., Carlisle, Anne E., Philips, Darci, Vazquez, Gustavo, Mukherjee, Nilanjan, Busman-Sahay, Kathleen, Nekorchuk, Michael, Terry, Margaret, Younger, Skyler, Bosse, Marc, Demeter, Janos, Rodig, Scott J., Tzankov, Alexandar, Goltsev, Yury, McIlwain, David Robert, Angelo, Michael, Estes, Jacob D., Nolan, Garry P.

“…Understanding the mechanisms of HIV tissue persistence necessitates the ability to visualize tissue microenvironments where infected cells reside; however,…”
Get full text

A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer by Monjazeb, Arta M, Giobbie-Hurder, Anita, Lako, Ana, Thrash, Emily M, Brennick, Ryan C, Kao, Katrina Z, Manuszak, Claire, Gentzler, Ryan D, Tesfaye, Anteneh, Jabbour, Salma K, Alese, Olatunji B, Rahma, Osama E, Cleary, James M, Sharon, Elad, Mamon, Harvey J, Cho, May, Streicher, Howard, Chen, Helen X, Ahmed, Mansoor M, Mariño-Enríquez, Adrian, Kim-Schulze, Seunghee, Gnjatic, Sacha, Maverakis, Emanual, Marusina, Alina I, Merleev, Alexander A, Severgnini, Mariano, Pfaff, Kathleen L, Lindsay, James, Weirather, Jason L, Ranasinghe, Srinika, Spektor, Alexander, Rodig, Scott J, Hodi, Stephen F, Schoenfeld, Jonathan D

“…Prospective human data are lacking regarding safety, efficacy, and immunologic impacts of different radiation doses administered with combined PD-L1/CTLA-4…”
Get full text

Integrated molecular drivers coordinate biological and clinical states in melanoma by Conway, Jake R., Dietlein, Felix, Taylor-Weiner, Amaro, AlDubayan, Saud, Vokes, Natalie, Keenan, Tanya, Reardon, Brendan, He, Meng Xiao, Margolis, Claire A., Weirather, Jason L., Haq, Rizwan, Schilling, Bastian, Stephen Hodi, F., Schadendorf, Dirk, Liu, David, Van Allen, Eliezer M.

“…We performed harmonized molecular and clinical analysis on 1,048 melanomas and discovered markedly different global genomic properties among subtypes ( BRAF ,…”
Get full text

Study of parasite kinetics with antileishmanial drugs using real-time quantitative PCR in Indian visceral leishmaniasis by Sudarshan, Medhavi, Weirather, Jason L., Wilson, Mary E., Sundar, Shyam

“…Objectives This study describes parasite kinetics in the blood of visceral leishmaniasis patients treated with liposomal amphotericin B (L-AmB) or a preformed…”
Get full text

Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates by Haddox, Candace L, Nathenson, Michael J, Mazzola, Emanuele, Lin, Jia-Ren, Baginska, Joanna, Nau, Allison, Weirather, Jason L, Choy, Edwin, Marino-Enriquez, Adrian, Morgan, Jeffrey A, Cote, Gregory M, Merriam, Priscilla, Wagner, Andrew J, Sorger, Peter K, Santagata, Sandro, George, Suzanne

“…Eribulin modulates the tumor-immune microenvironment via cGAS-STING signaling in preclinical models. This non-randomized phase II trial evaluated the…”
Get full text

Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer by Ricciuti, Biagio, Lamberti, Giuseppe, Puchala, Sreekar R, Mahadevan, Navin R, Lin, Jia-Ren, Alessi, Joao V, Chowdhury, Alexander, Li, Yvonne Y, Wang, Xinan, Spurr, Liam, Pecci, Federica, Di Federico, Alessandro, Venkatraman, Deepti, Barrichello, Adriana P, Gandhi, Malini, Vaz, Victor R, Pangilinan, Andy J, Haradon, Danielle, Lee, Elinton, Gupta, Hersh, Pfaff, Kathleen L, Welsh, Emma L, Nishino, Mizuki, Cherniack, Andrew D, Johnson, Bruce E, Weirather, Jason L, Dryg, Ian D, Rodig, Scott J, Sholl, Lynette M, Sorger, Peter, Santagata, Sandro, Umeton, Renato, Awad, Mark M

“…Although immune checkpoint inhibitors (ICI) have extended survival in patients with non-small-cell lung cancer (NSCLC), acquired resistance (AR) to ICI…”
Get full text